Terns Pharmaceuticals(TERN) - 2024 Q4 - Annual Results

Exhibit 99.1 TERN-701: Oral, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML) • Dose escalation in Phase 1 CARDINAL study completed in January 2025 • Terns previously announced positive interim data from the Phase 1 CARDINAL trial of TERN-701, demonstrating: o Compelling molecular responses starting at the lowest dose in heavily pre-treated CML patients with high baseline BCR-ABL transcript levels o Encouraging safety profile with no dose limiting toxicities, adverse eve ...